| Literature DB >> 30938713 |
Victoria H Cruz1, Emily N Arner1, Wenting Du1, Alberto E Bremauntz2, Rolf A Brekken1,3.
Abstract
Pancreatic ductal adenocarcinoma (PDA) is characterized by an activating mutation in KRAS. Direct inhibition of KRAS through pharmacological means remains a challenge; however, targeting key KRAS effectors has therapeutic potential. We investigated the contribution of TANK-binding kinase 1 (TBK1), a critical downstream effector of mutant active KRAS, to PDA progression. We report that TBK1 supports the growth and metastasis of KRAS-mutant PDA by driving an epithelial plasticity program in tumor cells that enhances invasive and metastatic capacity. Further, we identify that the receptor tyrosine kinase Axl induces TBK1 activity in a Ras-RalB-dependent manner. These findings demonstrate that TBK1 is central to an Axl-driven epithelial-mesenchymal transition in KRAS-mutant PDA and suggest that interruption of the Axl-TBK1 signaling cascade above or below KRAS has potential therapeutic efficacy in this recalcitrant disease.Entities:
Keywords: Cancer; Oncology
Year: 2019 PMID: 30938713 PMCID: PMC6538328 DOI: 10.1172/jci.insight.126117
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708